Arcus Biosciences (RCUS) Competitors $11.50 0.00 (0.00%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$11.40 -0.10 (-0.83%) As of 09/12/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. TGTX, MRUS, CRSP, PTCT, KRYS, PCVX, ACAD, ACLX, ADMA, and ARWRShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include TG Therapeutics (TGTX), Merus (MRUS), CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Its Competitors TG Therapeutics Merus CRISPR Therapeutics PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals TG Therapeutics (NASDAQ:TGTX) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Which has more volatility & risk, TGTX or RCUS? TG Therapeutics has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Is TGTX or RCUS more profitable? TG Therapeutics has a net margin of 13.31% compared to Arcus Biosciences' net margin of -109.56%. TG Therapeutics' return on equity of 26.05% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics13.31% 26.05% 9.58% Arcus Biosciences -109.56%-55.96%-25.73% Which has higher valuation and earnings, TGTX or RCUS? TG Therapeutics has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$454.07M11.24$23.38M$0.3786.92Arcus Biosciences$262M4.67-$283M-$3.17-3.63 Does the media refer more to TGTX or RCUS? In the previous week, Arcus Biosciences had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 10 mentions for Arcus Biosciences and 9 mentions for TG Therapeutics. Arcus Biosciences' average media sentiment score of 1.25 beat TG Therapeutics' score of 1.04 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TGTX or RCUS? TG Therapeutics presently has a consensus price target of $46.25, suggesting a potential upside of 43.81%. Arcus Biosciences has a consensus price target of $21.14, suggesting a potential upside of 83.85%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do insiders and institutionals hold more shares of TGTX or RCUS? 58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryTG Therapeutics beats Arcus Biosciences on 10 of the 15 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesMED IndustryMedical SectorNYSE ExchangeMarket Cap$1.22B$3.19B$5.84B$21.58BDividend YieldN/A2.30%5.68%3.49%P/E Ratio-3.6321.4375.4129.75Price / Sales4.67429.44515.8186.27Price / CashN/A46.6837.5625.00Price / Book2.179.6112.154.58Net Income-$283M-$53.29M$3.29B$999.94M7 Day Performance-5.89%0.13%0.74%0.68%1 Month Performance15.83%5.55%5.00%4.02%1 Year Performance-35.93%10.44%62.53%16.39% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences2.034 of 5 stars$11.50flat$21.14+83.9%-36.0%$1.22B$262M-3.63500Positive NewsTGTXTG Therapeutics4.2147 of 5 stars$32.38+0.5%$46.25+42.8%+35.5%$5.11B$329M87.51290Positive NewsInsider TradeMRUSMerus2.8969 of 5 stars$67.19-0.4%$88.75+32.1%+38.8%$5.10B$36.13M-12.2237Positive NewsCRSPCRISPR Therapeutics3.2862 of 5 stars$54.10-1.4%$71.60+32.3%+15.0%$4.99B$37.31M-9.96460News CoveragePositive NewsPTCTPTC Therapeutics3.6612 of 5 stars$56.95-0.5%$69.00+21.2%+79.7%$4.55B$806.78M8.171,410News CoveragePositive NewsInsider TradeKRYSKrystal Biotech4.9275 of 5 stars$145.20-3.4%$210.38+44.9%-28.7%$4.35B$290.52M29.51210Positive NewsPCVXVaxcyte2.3714 of 5 stars$32.41-1.8%$130.00+301.1%-72.3%$4.29BN/A-7.89160News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.3757 of 5 stars$25.39+0.5%$28.88+13.7%+44.7%$4.26B$957.80M19.09510News CoverageAnalyst ForecastACLXArcellx2.3652 of 5 stars$71.11-2.1%$114.31+60.7%-0.9%$4.03B$107.94M-20.7980News CoveragePositive NewsADMAADMA Biologics3.7009 of 5 stars$16.42-2.7%$27.67+68.5%-10.9%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1434 of 5 stars$27.17-6.6%$43.14+58.8%+38.3%$4.02B$3.55M-21.23400Analyst Revision Related Companies and Tools Related Companies TG Therapeutics Competitors Merus Competitors CRISPR Therapeutics Competitors PTC Therapeutics Competitors Krystal Biotech Competitors Vaxcyte Competitors ACADIA Pharmaceuticals Competitors Arcellx Competitors ADMA Biologics Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCUS Stock Alerts